Immutep (ASX:IMM) completed the enrolment target of 40 patients for the EFTISARC-NEO second phase trial in Warsaw, Poland, according to a Wednesday filing with the Australian bourse.
The EFTISARC-NEO trial is evaluating the immunotherapy eftilagimod alpha in combination with radiotherapy Keytruda in the neoadjuvant setting for patients with resectable soft tissue sarcoma, the filing said.
It earlier reported that the combination achieved a greater than three-fold increase in tumor hyalinization/fibrosis at the time of surgical resection among 21 patients available for primary endpoint assessment.
Data updates from the trial are expected in 2025, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.